In a previous publication, afatinib (an epidermal growth factor receptor inhibitor) effectively decreased the viability of BRAFV600E mutant colon cancer either in EGFR-wildtype or EGFR-mutated cells56. This evidence concerns the gene EGFR and colonic neoplasm.